Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 14/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 3/20 | 0.40 |
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | PDE11A | Q9HCR9 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184798 | 0.94 | GBA1 (0.55) | GBA1MAPTALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL16184723 | 0.92 | GBA1 (0.53) | GBA1MAPTALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL16184814 | 0.91 | GBA1 (0.52) | GBA1MAPTALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL16184782 | 0.89 | GBA1 (0.53) | GBA1MAPTALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL16184765 | 0.89 | GBA1 (0.53) | GBA1MAPTALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL16184731 | 0.88 | ALDH1A1 (0.49) | GBA1MAPTALDH1A1SMN1; SMN2PDE2A | |
| SCHEMBL16184699 | 0.87 | GBA1 (0.54) | GBA1MAPTALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL16184750 | 0.86 | GBA1 (0.51) | GBA1MAPTALDH1A1SMN1; SMN2ADRB2 | |
| SCHEMBL16184532 | 0.82 | CYP1A2 (0.49) | GBA1ALDH1A1PDE2APDE5APDE11A | |
| SCHEMBL16184796 | 0.81 | ALDH1A1 (0.50) | GBA1MAPTALDH1A1SMN1; SMN2PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | GBA1 1316/4885MAPT 509/4885ALDH1A1 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.